Unity Biotechnology Inc

Unity Biotechnology — Technical Presentation (July 2021)

26 slides from Unity Biotechnology's technical presentation, Jul 7, 2021

  1. Slide 1: UBX1325 Phase 1 Data Conference Call

    1 UBX1325 Phase 1 Data Conference Call July 6th, 2021 Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.2

  2. Slide 2: Special Note Regarding Forward-Looking Statements

    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop th

  3. Slide 3: UBX1325 provides an opportunity for a transformative, disease-modifying therapy

    3 PATIENT 232-0009 DME, 5 µg UBX1325 "The imaging data demonstrating structural improvements in the retina are compelling at this stage of clinical development and represent defined endpoints for disease improvement…" Jeffrey Heier, M.D. Director of the Vitreoretinal Service and Retina Research, Oph

  4. Slide 4: UBX1325 Phase 1 Data Highlights and Implications

    4 UBX1325 PROVIDES AN OPPORTUNITY FOR A TRANSFORMATIVE, DISEASE-MODIFYING THERAPY FOR DME AND nAMD PATIENTS Built on UNITY’s Senescent Cell Biology Platform UBX1325, the first senolytic drug being explored in eye disease, had a favorable safety and tolerability profile Initial efficacy data show rap

  5. Slide 5: Unity is developing transformative medicines to slow, halt, or reverse diseases of aging

    NEUROLOGY: Alzheimer’s, FTD, PSP (and other Tauopathies), ALS, Cognitive Disorders OPHTHALMOLOGY: DME, AMD, Diabetic Retinopathy UNITY IS DEVELOPING TRANSFORMATIVE MEDICINES TO SLOW, HALT, OR REVERSE DISEASES OF AGING 5 Targeting cellular senescence and aging-related biology

  6. Slide 6: Senescent cells affect the tissue micro-environment to drive disease progression

    SENESCENT CELLS AFFECT THE TISSUE MICRO-ENVIRONMENT TO DRIVE DISEASE PROGRESSION 6 Senescence-Associated Secretory Phenotype1 INFLAMMATORY FACTORS (e.g., TNF-α, IL-1α, IL-1β, IL-6, CCL11) PRO-FIBROTIC FACTORS (e.g., TGFβ1, TIMP-1, MCP-1, MMPs) GROWTH FACTORS (e.g., VEGF-A, PDGF, IL-8, PAI-1) CELLULA

  7. Slide 7: Unity is developing senolytic medicines to eliminate senescent cells

    UNITY IS DEVELOPING SENOLYTIC MEDICINES TO ELIMINATE SENESCENT CELLS TO RESTORE TISSUE HEALTH 7 Functional Cell Senescent Cell (SnC) Cytokines, chemokines & matrix remodeling factors (SASP) Macrophage CD4+ T lymphocyte Fibroblast Target Senescent Cells and neutralize SASP factors to eliminate root c

  8. Slide 8: Therapeutic hypothesis: elimination of vascular senescent cells by UBX1325

    THERAPEUTIC HYPOTHESIS: ELIMINATION OF VASCULAR SENESCENT CELLS BY UBX1325 SHOULD RE-ESTABLISH BARRIER FUNCTION AND REVERSE DISEASE PROGRESSION IN DME AND nAMD PATIENTS UBX1325 8

  9. Slide 9: UBX1325 targets a node upstream of anti-VEGF therapies

    UBX1325 TARGETS A NODE UPSTREAM OF ANTI-VEGF THERAPIES 9 UBX1325 Modified from Urias et al. Vision Res 2017;139:221-227 and Das et al. Ophthalmology 2015;122:1375-1394. Inflammatory Microenvironment PDGF INTEGRINS BFGF Ang2 HGF MMP IL1�� IL6 KKS ICAM-1 IL1�� VEGF MCP-1

  10. Slide 10: UBX1325 provides an opportunity for a transformative best-in-disease therapy

    UBX1325 PROVIDES AN OPPORTUNITY FOR A TRANSFORMATIVE BEST-IN-DISEASE THERAPY 10 UBX1325 Rapid effect with greater efficacy and durability than SoC Aspirational Treatment Benefits for DME and nAMD Patients Potential for disease modification Novel MOA and favorable pharmacology Able to use in combinat

  11. Slide 11: UBX1325 Phase 1 Trial Design and Summary Data

    UBX 1325 Phase 1 Trial Design and Summary Data Initial 12 Patients in SAD Study 11 Data presented are preliminary reads prior to fully monitoring, validating, and locking the data sets.

  12. Slide 12: UBX1325 Clinical Program

    UBX1325 CLINICAL PROGRAM 2020 2021 2022 Long-Term Follow-up Phase 2a DME Study First patient dosed June 2021 SAFETY & TOLERABILITY DOSE, EFFICACY & DURABILITY 12 Single Injection of UBX1325 24-week Follow-up Phase 1 SAD Study - up to 10 µg Phase 2a nAMD Study* 2023+ *Study under consideration

  13. Slide 13: Study UBX1325-01: Single ascending dose safety study in DME or nAMD

    STUDY UBX1325-01: SINGLE ASCENDING DOSE SAFETY STUDY IN PATIENTS WITH ADVANCED DME OR nAMD 13 Cohort 1 0.5 µg/eye n=3 Cohort 2 1.0 µg/eye n=3 Cohort 4 5.0 µg/eye n=3 Cohort 5 10 µg/eye n=3 Study Population Advanced DME or nAMD with BCVA of 20/80 (55 ETDRS letters) or worse in the first 2 cohorts; 20

  14. Slide 14: Executive Summary: UBX1325 Phase 1 SAD Study

    EXECUTIVE SUMMARY: UBX1325 PHASE 1 SAD STUDY 14

  15. Slide 15: UBX1325 was well-tolerated through all doses

    UBX1325 WAS WELL-TOLERATED THROUGH ALL DOSES 15 Safety and Tolerability acceptable to advance to additional clinical studies with UBX1325 in ocular diseases * Same patients, not treatment-related

  16. Slide 16: Rapid increase in BCVA among high dose cohorts after single dose

    BY 4 WEEKS, PATIENTS SHOW RAPID INCREASE IN BCVA AMONGST HIGH DOSE COHORTS AFTER SINGLE DOSE UBX1325 16

  17. Slide 17: Rapid increase in BCVA among high dose cohorts after single dose

    BY 4 WEEKS, PATIENTS SHOW RAPID INCREASE IN BCVA AMONGST HIGH DOSE COHORTS AFTER SINGLE DOSE UBX1325 17 Not a head-to-head trial.

  18. Slide 18: Majority of patients show decrease in CST among high dose cohorts

    BY 4 WEEKS, MAJORITY OF PATIENTS SHOW DECREASE IN CST AMONGST HIGH DOSE COHORTS AFTER SINGLE DOSE UBX1325 18

  19. Slide 19: Examples of Imaging Data

    Examples of Imaging Data 19 Normal Optical Coherence Tomograph (OCT)

  20. Slide 20: DME Patient 232-0009: BCVA improved, CST decreased

    DME PATIENT 232-0009, 5 µg BCVA IMPROVED, CST DECREASED 20 Baseline Week 4 CST REDUCED Registered Image Registered Image

  21. Slide 21: DME Patient 232-0008: BCVA improved, CST decreased

    DME PATIENT 232-0008, 5 µg BCVA IMPROVED, CST DECREASED 21 Baseline Week 4 Central Cyst Hyperreflective Foci Registered Image Registered Image

  22. Slide 22: nAMD Patient 230-0007: BCVA improved, CST and SRF reduced

    nAMD PATIENT 230-0007: 1 µg BCVA IMPROVED, CST AND SRF REDUCED 22 Baseline Week 8 Hyperreflective foci

  23. Slide 23: nAMD Patient 229-0012: BCVA improved, CST and SRF reduced

    nAMD PATIENT 229-0012: 5 µg BCVA IMPROVED, CST AND SRF REDUCED 23 Baseline Week 4 subretinal fluid Registered Image Registered Image

  24. Slide 24: Executive Summary: UBX1325 Phase 1 SAD Study

    EXECUTIVE SUMMARY: UBX1325 PHASE 1 SAD STUDY 24

  25. Slide 25: UBX1325 provides an opportunity for a transformative, disease-modifying therapy

    25 PATIENT 232-0009 DME, 5 µg UBX1325 "The imaging data demonstrating structural improvements in the retina are compelling at this stage of clinical development and represent defined endpoints for disease improvement…" Jeffrey Heier, M.D. Director of the Vitreoretinal Service and Retina Research, Op

  26. Slide 26: UBX1325 Ph1 Data Conference Call Q&A

    26 UBX1325 Ph1 Data Conference Call Q&A July 6th, 2021 Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO

Unity Biotechnology — Technical Presentation (July 2021) on 6ix